The present invention is concerned with measures for tumor therapy. In particular, contemplated is an inhibitor of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer. The invention, furthermore, relates to a medicament comprising said inhibitor of RAGE and, preferably, a pharmaceutically acceptable carrier. Further, the invention encompasses a method for identifying a subject in need of treatment with an inhibitor of RAGE, comprising determining in a sample from said subject the amount of RAGE, comparing said amount of RAGE determined in step a) with a reference amount, and identifying a subject in need of treatment with an inhibitor of RAGE. The invention also relates to a device for identifying a subject in need of treatment with an inhibitor of RAGE, as well as a kit adapted to carry out the method of the present invention, said kit comprising instructions for carrying out the aforementioned method.
